Targeting adenosine for cancer immunotherapy

Table 2 Overview of clinical trials investigating targets within the adenosine signaling pathway in cancer

Molecular Target	ClinicalTrials.gov Identifier	Pharmaceutical Supplier	Agent	Design Overview
Interventional Trials
A2aR	NCT02655822	Corvus	CPI-444	Phase 1/1b	single agent and in combination with Atezolizumab	allows prior PD-1/PD-L1	advanced solid malignancies
	NCT02403193	Pablobio (Novartis)	PBF-509	Phase 1/1b	single agent and in combination PDR001 (anti-PD1)	allows prior PD-1/PD-L1	non-small cell lung cancer
	NCT03099161	Merck	MK-3814	Phase 1	single agent and in combination with Pembrolizumab(anti-PD-1);	allows prior PD-1/PD-L1	advanced solid malignancies
	NCT02740985	AstraZeneca	AZD4635	Phase 1	single agent and in combination with Durvalumab (anti-PDL-1)	allows prior PD-1/PD-L1	advanced solid malignancies
CD73	NCT02503774	Medimmune	MEDI9447	Phase 1	combination with Durvalumab (anti-PDL-1) (no single agent)	allows prior PD-1/PD-L1	advanced solid malignancies
	NCT03267589	Medimmune	MEDI9447	Phase 2	single agent and in combination with Durvalumab (anti-PDL-1), Tremelilumab (anti-CTLA4), MEDI 0562 (anti-OX40)	allows prior PD-1/PD-L1	relapsed ovarian cancer
	NCT02754141	Bristol-Meyers-Squibb	BMS-986179	Phase 1/2a	single agent and in combination with Nivolumab (anti-PD-1)	allows prior PD-1/PD-L1	advanced solid malignancies
Noninterventional Trials^a
CD39/CD73	NCT03255252	Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
CD39/CD73	NCT02567929	Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patients With Breast Cancer

^a“Noninterventional trials” refers to interventions targeting the adenosine-CD39-CD73-A2aR pathway, these trials may be otherwise interventional in terms of other treatment modalities, such as chemotherapy or radiation